Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer

Future Oncology

Volumn 9, Issue 6, 2013, Pages 899-907

  Lucarelli, Giuseppe ^a   Ditonno, Pasquale ^a   Bettocchi, Carlo ^a   Spilotros, Marco ^a   Rutigliano, Monica ^a   Vavallo, Antonio ^a   Galleggiante, Vanessa ^a   Fanelli, Margherita ^b   Larocca, Angela Maria Vittoria ^b   Germinario, Cinzia Annatea ^b   Maiorano, Eugenio ^b   Selvaggi, Francesco Paolo ^a   Battaglia, Michele ^a  

^a Urology Clinic   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

biomarker; cancer metabolism; castration resistant prostate cancer; docetaxel; serum sarcosine

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SARCOSINE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DISEASE DURATION; ELECTROCORTICOGRAPHY; GLEASON SCORE; HORMONE SENSITIVITY; HUMAN; MAJOR CLINICAL STUDY; MCGILL PAIN QUESTIONNAIRE; METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL;

AGED; ANTINEOPLASTIC AGENTS; CASTRATION; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS; SARCOSINE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878513309     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.50     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J. Clin. 63(1), 11-30 (2013).
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specifc survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urologic Clin. North Am. 28(3), 555-565 (2001).
3. Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004).
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004).
5. Armstrong AJ, Eisenberger MA, Halabi S et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur. Urol. 61(3), 549-559 (2012).
6. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910-914 (2009).
7. Jentzmik F, Stephan C, Miller K et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identifcation of aggressive tumours. Eur. Urol. 58(1), 12-18; discussion 20-11 (2010).
8. Wu H, Liu T, Ma C et al. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal. Bioanal. Chem. 401(2), 635-646 (2011).
9. Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XD. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis. 14(2), 166-172 (2011).
10. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA. Serum sarcosine is not a marker for prostate cancer. Ann. Clin. Biochem. 47(Pt 3), 282 (2010).
11. Sreekumar A, Poisson LM, Rajendiran TM et al. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identifcation of aggressive tumours. Eur Urol 2010;58:12-8. Eur. Urol. 58(3), e29-e30; author reply e31-e32 (2010).
12. Colleselli D, Stenzl A, Schwentner C. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identifcation of aggressive tumours. Eur Urol 2010;58:12-8. Eur. Urol. 58(5), e29-e30 (2010).
13. Lucarelli G, Fanelli M, Larocca AM et al. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 72(15), 1611-1621 (2012).
14. Miyake M, Gomes Giacoia E, Aguilar Palacios D, Rosser CJ. Sarcosine, a biomarker for prostate cancer: ready for prime time? Biomark. Med. 6 (4), 513-514 (2012).
15. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J. Cell. Biochem. 90(3), 525-533 (2003).
16. 1H NMR spectroscopy at 9.4 T. FEBS Lett. 494(1-2), 112-116 (2001).
17. 1H HR-MAS spectroscopy. Magn. Reson. Med. 55(6), 1257-1264 (2006).
18. Trock BJ. Application of metabolomics to prostate cancer. Urol. Oncol. 29(5), 572-581 (2011).
19. Song YH, Shiota M, Kuroiwa K, Naito S, Oda Y. The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod. Pathol. 24(9), 1272-1280 (2011).
20. Stabler S, Koyama T, Zhao Z et al. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One 6(8), e22486 (2011).
21. Montrose DC, Zhou XK, Kopelovich L et al. Metabolic profling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev. Res. (Phila.) 5(12), 1358-1367 (2012).
22. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specifc antigen and pain surrogacy ana lysis in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 25(25), 3965-3970 (2007).
23. Halabi S, Vogelzang NJ, Kornblith AB et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J. Clin. Oncol. 26(15), 2544-2549 (2008).
24. Armstrong A, Garrett-Mayer ES, Yang OY et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX 327 study ana lysis. Clin. Cancer Res. 13(21), 6396-6403 (2007).
25. Gu H, Gowda GN, Raftery D. Metabolic profling: are we en route to better diagnostic tests for cancer? Future Oncol. 8 (10), 1207-1210 (2012).